Rex Bionics plc – Proposed Fundraising and Notice of General Meeting

Placing and Subscription to raise £2.1 million and proposed Additional Fundraising to raise approximately £1.0 million and Share Restructuring. Link here. 12 June 2015 Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, today announces a proposed Placing and Subscription of 3,500,000 New Ordinary Shares at […]

AmpliPhi Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization

Results presented at the 38th European Cystic Fibrosis Conference Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 12, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. […]

SeaDragon Full Year Result to 31 March 2015

FINANCIAL RESULTS FOR THE 12 MONTHS TO 31 MARCH 2015. Link here. SeaDragon annual sales double; Omega 3 refinery on track for start-up in Q4 2015 Highlights: • New Omega 3 fish oil refinery on track for commissioning later this year, realising a 10 year strategic plan • Additional Squalene raw material supply contracts position SeaDragon for […]

AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage

Results to be presented at the 38th European Cystic Fibrosis Conference. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 8, 2015 – AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of […]

Nexvet Advances Manufacturing Strategy

Nexvet Advances Manufacturing Strategy. Link here. Agreement signed with FUJIFILM Diosynth Biotechnologies Key appointment made in Ireland DUBLIN, Ireland and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) — Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, announced today an update to its manufacturing strategy. Nexvet has signed a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to provide […]

Nexvet Announces Positive Top-Line Results for Proof-of-Concept Efficacy Study of NV-02 in Cats With Degenerative Joint Disease

DUBLIN, Ireland and MELBOURNE, Australia, June 4, 2015 (GLOBE NEWSWIRE) Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced statistically significant top-line results from its proof-of-concept (POC) efficacy study of NV-02, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy in development for the control of pain associated with degenerative joint disease (DJD), including […]

AmpliPhi’s Bacteriophage Manufacturing Facility Receives cGMP Certification

First cGMP-certified manufacturing facility commissioned to manufacture bacteriophage products for human use. Link here. San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, June 3, 2014 – AmpliPhi BioSciences Corporation. (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that its production facility in Ljubljana, Slovenia, was […]

Rex Bionics – First Patient Treated in RAPPER II Clinical Trial

1 June 2015 Rex Bionics Plc (AIM: RBX), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce that the first patient has been successfully treated in its RAPPER II (“Robot-Assisted PhysiotheraPy Exercises with REX”) clinical trial. Link here. A 37 year-old male with a spinal cord injury at level T3, […]

Rex Bionics – Audited Results period ended 31 Mar 2015

29 May 2015, Rex Bionics Plc (AIM: RXB) the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users and enables robot assisted physiotherapy exercise, today announces its audited results for the sixteen month period ending 31 March 2015. Link here.

AmpliPhi Provides Corporate Update and Reports First Quarter 2015 Financial Results

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, May 19 2015 Link here. AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today provided a corporate update and announced financial results for the first quarter ended March 31, 2015. Corporate Update • […]